Insulet Corp (FRA:GOV)
€ 258.8 0.4 (0.15%) Market Cap: 18.10 Bil Enterprise Value: 18.57 Bil PE Ratio: 47.22 PB Ratio: 17.30 GF Score: 90/100

Insulet Corp at Canaccord Genuity Medical Technologies & Diagnostics Forum (Virtual) Transcript

Nov 19, 2020 / 05:30PM GMT
Release Date Price: €223.1 (+2.01%)
Kyle William Rose
Canaccord Genuity Corp., Research Division - Senior Analyst

Good afternoon, and thank you for joining us at this year's Canaccord Genuity Medical Technology and Diagnostics Forum. My name is Kyle Rose. I'm on the MedTech team here at Canaccord Genuity. And joining us this afternoon is Insulet, who is a top player in the insulin pump market with its novel form factor and pay-as-you-go business model.

The company recently delivered strong Q3 results and with a new product cycle on the horizon, looks to be entering an exciting period of execution. So with us this afternoon are several members of management, including Wayde McMillan, CFO; Bret Christensen, CCO; as well as Deb Gordon, VP of Investor Relations.

Before we kick it off, the lawyers and my compliance team always request that I mention any relevant disclosures, if and where applicable, they can be found in our conferencing or firm website. So with that, I'll jump into some discussion. It's going to be back and forth Q&A with some fireside. So if the investors on the line want to submit questions to the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot